UNITED STATES PATENT AND TRADEMARK OFFICE Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
Washington, D.C. 20231 U.S. APPLICATION NO. PIRST NAMED APPLICANT INTERNATIONAL APPLICATION NO. 7/01424 022850 5071 OBLON SPIVAK MCCLELLAND MAIER & NEU FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY I.A. PILINO DATE / 16/98 ARLINGTON VA 22202

	04/05/01
	DATE MAILED:
	UIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED ITED/ELECTED OFFICE (DO/EO/US)
1. The following items have been submitted by the	applicant or the IB to the United States Patent and Trademark
U.S. Basic National Fee.	1.494) an Elected Office (37 CFR 1.495): Indication of Small Entity Status.
Copy of the international application.	Translation of the international application into English.
Oath or Declaration of inventors(s).	Translation of Article 19 amendments into English.
Copy of Article 19 amendments.	Other:
Priority Document.	_
	ation Report in English and its Annexes, if any.
Translation of Annexes to the Internati	onal Preliminary Examination Report into English.
	er 35 U.S.C. 371(f) but has not filed the following indicated items and/or ic National Fee and the copy of the international application must be filed void abandonment. Copy of the international application.
 The following items MUST be furnished within acceptance under 35 U.S.C. 371: 	the period set forth below in order to complete the requirements for
	nglish. A processing fee will be required if submitted
<u> </u>	0 months from the priority date. ve for the reasons indicated on the attached Notice of Defective
Translation. b. Processing fee for providing the translation.	nslation of the application and/or the Annexes later than the
appropriate 20 or 30 months from	the priority date (37 CFR 1.492(f)).
 -	in compliance with 37 CFR 1.497(a) and (b), properly identifying
	International application number and international filing date). A nitted later than the appropriate 20 or 30 months from the priority
	oes not comply with 37 CFR 1.497(a) and (b) for the reasons O/EO/917.
	declaration later than the appropriate 20 or 30 months from the
4. Additional claim fees of \$ as a _	large entity small entity, including any required multiple dependent
claim fee, are required. Applicant must submit the due (37 CFR 1.492(g)). See attached PTO-875.	additional claim fees or cancel the additional claims for which fees are
 Applicant has not submitted the required sequence PCT/DO/EO/920. 	uence listing pursuant to 37 CFR 1.821-1.825. See attached
MONTHS FROM THE DATE OF THIS NOTIC), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) CE OR BY 22 OR 32 MONTHS (where 37 CFR 1,495 applies) FROM ION, WHICHEVER IS LATER. FAILURE TO PROPERLY TT.
The time period set above may be extended by filin 1.136(a).	g a petition and fee for extension of time under the provisions of 37 CFR
Annexes will be cancelled. A processing fee will b	Annexes MUST be submitted no later than the time period set above or the se required if submitted later than 20 or 30 months from the priority dete. see a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) date.
	ne United States Patent and Trademark Office must be mailed to the
	MITTER he net word with this
	MUST be returned with this response. Dutice of Defective Translation
	T/DO/EO/920
	Barbara Campbell, Paralegal
FORM PCT/DO/EO/905 (March 2001)	Telephone: 703 305-3631

07/16/99

04/05/01

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of América. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw
Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:
APPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
A statement that the contents of the paper or compact disc and the computer readable form
are the same and, where applicable, include no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:
(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Barbara Campbell, Paralegal

Telephone: 703 305-3631